I think in the orphan-drug space, the prices of these technologies are so high that relatively few people have the ability to sustain the premiums they have to pay. I think as a general principle, medicines for severe orphan conditions should be on the essential medicines list and should be provided publicly. Access to them shouldn't be a function of your socio-economic good fortune. The public should pay for them following very structured, clear criteria. It's not very good to use the routine data infrastructure to get the evidence and the clear clinically driven but value-informed basis for stop-starts with those technologies. If we don't do that, I think we're missing a real opportunity.
On May 30th, 2016. See this statement in context.